

Special Issue

Combining Immunotherapy with Radiotherapy for Cancer Treatment: Current Challenges and Future Directions

Message from the Guest Editor

The combination of two major pillars of cancer treatment, radiotherapy and immunotherapy, has opened the door to numerous treatment possibilities. Each pillar is unique in its own way and advancing at a fast rate. Yet, radioimmunotherapy (RIT) also presents a unique set of challenges: When should RIT be used and what criteria should be applied? What type of immunotherapy should be used in combination with RT? What dose and fractionation regimen should be used with a selected immunotherapy? How should the two therapies be arranged and at what frequency: sequential, concurrent? Which cell population(s) is involved with each therapy and how do these cell populations interact when the two therapies are combined? What pathways are implicated and does acquired resistance develop? These are some of the questions that need to be addressed in order to advance the field of RIT. In this Special Issue, titled Combining Immunotherapy with Radiotherapy for Cancer Treatment: Current Challenges and Future Directions, we wish to shed light on the emerging field of RIT. We are eager to read your submissions and publish them in this Special Issue.

Guest Editor

Prof. Dr. Ayman J. Oweida

Department of Nuclear Medicine and Radiobiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada

Deadline for manuscript submissions

closed (28 January 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/93050

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp
Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).